Precision or personalized medication is mostly about picking patients with a specific protein or genomic biomarker who might take advantage of a therapy that is particular.
So does using a biomarker to choose patients for phase 1 trials effectiveness that is improve?
Maria Schwaederle, Pharm. D., associated with University of Ca, San Diego, and coauthors explored that appropriate question in a meta-analysis of 346 trials and 13,203 clients.
The writers examined reaction price and survival that is progression-free maybe not general success as a result of inadequate data. They compared trials that used a approach that is personalized a biomarker selection with those who would not.
The authors report their analysis suggests a personalized medicine approach had been associated with improved results, with a greater median response price and longer survival that is progression-free. Furthermore, the biomarker that has been used seemed to matter, with a genomic DNA biomarker associated with a higher response that is median than a protein biomarker, in line with the outcomes. Trial arms that would not make use of a biomarker had response that is median comparable to the ones that tested a cytotoxic chemotherapy agent, the authors report.
The authors note study limits within their meta-analysis, such as including trial that is just that reported single agents, maybe not analyzing combination treatment, rather than analyzing success as a finish point.
"These results argue highly for the enrichment of phase 1 studies being clinical biomarker selection for targeted therapies. However, rigid exclusion centered on biomarkers which have maybe not proven clinically could prove counterproductive in some cases," the authors conclude.
Article: Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis, Maria Schwaederle, PharmD; Melissa Zhao, BS; J. Jack Lee, PhD; Vladimir Lazar, PhD; Brian Leyland-Jones, MD; Richard L. Schilsky, MD; John Mendelsohn, MD; Razelle Kurzrock, MD, JAMA Oncology, doi: 10.1001/jamaoncol.2016.2129, published 6 2016 june.